[311 Pages Report] Exhibiting a Y-o-Y growth rate of 10.9%, the global antidiabetics market is expected to garner US$ 89.2 Billion in 2022, against US$ 80.4 Billion in 2021. The industry is estimated to reach US$ 223 Billion, displaying a CAGR of 9.6% during the assessment period from 2022 to 2032. The growing prevalence of diabetes across the globe is expected to be the most significant factor driving the global antidiabetics market during the stint of 2022 to 2032.
“Increasing diabetic cases across the globe with the rising geriatric population is expected to drive the market. Also, the rapid development of healthcare infrastructure in developing countries can further expand the market size in the forthcoming period.”
| Attributes | Details |
|---|---|
| Global Antidiabetics Market CAGR (2022 to 2032) | 9.6% |
| Global Antidiabetics Market Size (2022) | US$ 89.2 Billion |
| Global Antidiabetics Market Size (2032) | US$ 223 Billion |
As per International Diabetes Federation, the global diabetes incidence is anticipated to increase from 366 million in 2011 to 552 million by 2030. Such a significant rise in diabetic patients is expected to positively impact the market in the coming time. Other factors such as; the growing geriatric population, rising cases of obesity, and the development of new products are expected to benefit the market in the forecast period. For instance, in January 2022, Novo Nordisk, announced the launch of oral semaglutide in India for the treatment of Type 2 diabetes. Such initiatives taken by players to strengthen their reach in the global market are projected to benefit the market in the assessment period.
Additionally, the growing approval for antidiabetic drugs and a strong pipeline for antidiabetics are expected to offer significant opportunities for market expansion. The antidiabetic pipeline comprises SCO-094, Tirzepatide, Volagidemab, CT-388, GX G6, ORMD-0801, and others. Moreover, the increasing number of drug approvals by the FDA is projected to offer significant opportunities to the players. The number of therapeutic alternatives to treat T2DM is rising and there are about 60 drugs approved by the FDA. Further, there are approximately 100 additional antidiabetic agents being evaluated in clinical trials. Also, the standard treatments of insulin therapy and metformin, there are new drug combinations containing metformin, SGLT2 inhibitors, and dipeptidyl peptidase-4 (DPP4). Such factors are anticipated to benefit the market notably in the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing investment in drug development to tackle the growing incidences of diabetes is expected to propel the industry’s expansion in the forecast period. As per the European Society of Cardiology, the diabetic population is likely to reach 628.6 million by 2045. Therefore, there has been growing advancement in antidiabetic drugs that has resulted in growing success rates and reduced complications. For instance, in May 2022, the Food and Drug Administration approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar.
In addition, rising glucose intolerance with increasing age is expected to enhance the demand for antidiabetics amongst the geriatric population. Also, the expanding geriatric population is expected to generate significant demand for antidiabetics. With advancing age, the prevalence of Type 2 diabetes is increasing along with the enhanced risk of vascular diseases, coronary heart diseases, and stroke. Therefore, in order to regulate comorbidities along with the advancing age of baby boomers, the market is expected to benefit in the forecast time.
Furthermore, increasing investments in research and development by players are projected to support the market growth in the forecast period. In 2019, Glenmark launched an oral anti-diabetic drug Remogliflozin in India. The drug is effective in treating adults with Type-2 diabetes mellitus.
The rapid adoption of insulin pumps amongst diabetic patients is expected to offer significant market opportunities in the forecast period. The development of advanced pumps powered by smart technologies such as; AI and ML are expected to offer remunerative opportunities to the market. In July 2021, Ypsomed AG expanded the range of features of the mylife YpsoPump system. The app-based deployment of the Dexcom G6 Continuous Glucose Monitoring (CGM) System allows people with diabetes to manage their therapy through their smartphones.
Also, product approvals with the presence of a robust pipeline are projected to be another remunerative opportunity for market growth in the forecast period. The ongoing development in insulin pumps is likely to augment the market size and pose a lucrative opportunity. For instance, Tandem Diabetes, Inc. focuses on developing delivery device solutions to meet the requirement of people living with Type 1 and Type 2 diabetes. Mobi, t: slim X3, and Mobi: Tubeless are some of the products in the pipeline of Tandem Diabetes Care, Inc.
The growing awareness about the advanced insulin pumps among diabetic patients and the benefits associated with disease management is expected to boost the market growth in the assessment period.
Principal Consultant
High costs associated with the insulin pumps are expected to limit the market growth in the forecast period. As per an article published by Mdedge, insulin pumps are more expensive than daily injections. The estimated cost difference is 30%. The cost of these pumps involves additional costs of consumables such as batteries, sensors, and others. Moreover, lack of awareness about the treatment methods available and poor reimbursement policies in developing countries are other factors hindering the market growth in the assessment period.
However, clinical benefits offered by insulin pumps along with advanced features such as; integrated CGM sensors, smartphone connectivity, and other features, are expected to create the popularity of these pumps among healthcare professionals and patients suffering from diabetes.
Insulin Antidiabetics to be Most Sought After across the Coming Decade
As per the analysis, the global antidiabetics market, by product, is anticipated to be dominated by the Insulin segment. The segment is predicted to exhibit a CAGR of 9.4% in the assessment period. The growth of the segment can be attributed to the introduction of new products and the number of products in the pipeline.
Oral Ingestion of Antidiabetics to be Most Popular
Based on the route of administration, the oral segment is projected to lead the market in the forecast period. The segment is anticipated to expand at a growth rate of 9.5% in the assessment period. The development of the segment can be attributed to the introduction of new drugs and also the rapid rise in the Type-2 diabetes population.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Availability of a Wide Range of Insulin Drugs Propelling Expansion
As per the analysis, the global antidiabetics market is anticipated to be dominated by North America. In the region, the U.S is predicted to dominate the market in the forecast period. The region is estimated at US$ 79.6 Billion.
The growth of the market can be attributed to the penetration of modern insulin products that are long-lasting, rapid-acting insulin, and DPP-4 drugs such as Onglyza, Januvia, and Nesina. Also, approvals by FDA are expected to propel the market growth in the forecast period.
For instance, in May 2022, Eli Lilly obtained FDA approval for a diabetes drug that may also help with obesity. In addition, increased patient awareness levels, high healthcare expenditure, and reimbursement framework are other factors driving the industry growth in the forecast period. Such factors are expected to develop the market in the region.
High Diabetes Prevalence Rates driving Consumption across the U.K and China
Europe is anticipated to witness decent growth in the forecast period. The U.K is estimated at US$ 9.2 Billion. As per WHO, about 60 million people have been infected with the disease across Europe. The surging case across the region is projected to be the most important factor driving the market in the forecast period.
| Countries | Estimated CAGR |
|---|---|
| USA | 9.4% |
| UK | 8.3% |
| China | 8.9% |
| Japan | 7.9% |
| South Korea | 7.5% |
APAC is anticipated to be the most lucrative market during the forecast period. China is anticipated to lead the market in the forecast period. The country is estimated at US$ 16 Billion. Other anticipated lucrative countries are South Korea and Japan. Expansion of the regional market can be attributed to the growing prevalence of diabetes amongst the expanding geriatric population. Rising cases of diabetes can be attributed to the growing urbanization and adoption of a sedentary lifestyle. Also, the presence of developing countries is likely to aid in expanding the regional market growth.
Key players in the global antidiabetic market include Bayer Corporation, AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Bristol-Myers Squibb. Recent developments in the industry are:
The global antidiabetics market is estimated at US$ 89.2 Billion in 2022.
By product, insulin-based antidiabetics is projected to witness a CAGR of 9.4% by 2032.
Antidiabetic sales in South Korea are anticipated to reach US$ 8 Billion by 2032.
The expected market value from 2022- to 2032 is US$ 223 Billion.
The market in the U.S is anticipated to garner US$ 79.6 Billion by 2032.
China is projected to document a value CAGR of 8.9% by 2032 with regard to antidiabetic sales.
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. FMI Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Antidiabetics 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Mn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Antidiabetics Market, by Key Countries 4.2. Antidiabetics Market Opportunity Assessment (US$ Mn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Patch Management Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Patch Management Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Antidiabetics Market Demand Analysis 2015-2021 and Forecast, 2022-2032 6.1. Historical Market Analysis, 2015-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Antidiabetics Market Value Analysis 2015-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032, By Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2015-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032 8.3.1. Insulin 8.3.1.1. Rapid acting analog 8.3.1.2. Long acting analog 8.3.1.3. Premixed insulin 8.3.1.4. Short acting analog 8.3.1.5. Intermediate acting insulin 8.3.2. Drug class 8.3.2.1. Alpha glucosidase inhibitors 8.3.2.2. Biguanides 8.3.2.3. Sulphonylureas 8.3.2.4. GLP-1 (Glucagon like peptide) agonists 8.3.2.5. DPP-IV (Dipeptidyl Peptidase) inhibitors 8.3.2.6. Meglitinides 8.3.2.7. SGLT-II (Sodium Glucose Transport Proteins) inhibitors 8.3.2.8. Thiazolidinedione 8.4. Market Attractiveness Analysis By Product 9. Global Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032, By Patient Population 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Patient Population, 2015-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Patient Population, 2022-2032 9.3.1. Pediatric 9.3.2. Adult 9.3.3. Geriatric 9.4. Market Attractiveness Analysis By Patient Population 10. Global Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032, By Route of Administration 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032 10.3.1. Insulin syringe/ Insulin pen 10.3.2. Insulin pump 10.3.3. Intravenous infusion 10.3.4. Oral 10.3.5. Others 10.4. Market Attractiveness Analysis By Route of Administration 11. Global Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021 11.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. Asia Pacific 11.3.5. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 12.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 12.4.1. By Country 12.4.1.1. U.S. 12.4.1.2. Canada 12.4.1.3. Rest of North America 12.4.2. By Product 12.4.3. By Route of Administration 12.4.4. By Patient Population 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Product 12.5.3. By Route of Administration 12.5.4. By Patient Population 13. Latin America Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 13.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 13.4.1. By Country 13.4.1.1. Brazil 13.4.1.2. Mexico 13.4.1.3. Rest of Latin America 13.4.2. By Product 13.4.3. By Route of Administration 13.4.4. By Patient Population 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Product 13.5.3. By Route of Administration 13.5.4. By Patient Population 14. Europe Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 14.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. Germany 14.4.1.2. France 14.4.1.3. U.K. 14.4.1.4. Italy 14.4.1.5. Benelux 14.4.1.6. Nordic Countries 14.4.1.7. Rest of Europe 14.4.2. By Product 14.4.3. By Route of Administration 14.4.4. By Patient Population 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Product 14.5.3. By Route of Administration 14.5.4. By Patient Population 15. Asia Pacific Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 15.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 15.4.1. By Country 15.4.1.1. China 15.4.1.2. Japan 15.4.1.3. South Korea 15.4.1.4. Rest of Asia Pacific 15.4.2. By Product 15.4.3. By Route of Administration 15.4.4. By Patient Population 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Product 15.5.3. By Route of Administration 15.5.4. By Patient Population 16. Middle East and Africa Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 16.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. South Africa 16.4.1.3. Turkey 16.4.1.4. Rest of Middle East and Africa 16.4.2. By Product 16.4.3. By Route of Administration 16.4.4. By Patient Population 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Product 16.5.3. By Route of Administration 16.5.4. By Patient Population 17. Key Countries Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032 17.1. Introduction 17.1.1. Market Value Proportion Analysis, By Key Countries 17.1.2. Global Vs. Country Growth Comparison 17.2. US Antidiabetics Market Analysis 17.2.1. Value Proportion Analysis by Market Taxonomy 17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.2.2.1. By Product 17.2.2.2. By Route of Administration 17.2.2.3. By Patient Population 17.3. Canada Antidiabetics Market Analysis 17.3.1. Value Proportion Analysis by Market Taxonomy 17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.3.2.1. By Product 17.3.2.2. By Route of Administration 17.3.2.3. By Patient Population 17.4. Mexico Antidiabetics Market Analysis 17.4.1. Value Proportion Analysis by Market Taxonomy 17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.4.2.1. By Product 17.4.2.2. By Route of Administration 17.4.2.3. By Patient Population 17.5. Brazil Antidiabetics Market Analysis 17.5.1. Value Proportion Analysis by Market Taxonomy 17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.5.2.1. By Product 17.5.2.2. By Route of Administration 17.5.2.3. By Patient Population 17.6. Germany Antidiabetics Market Analysis 17.6.1. Value Proportion Analysis by Market Taxonomy 17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.6.2.1. By Product 17.6.2.2. By Route of Administration 17.6.2.3. By Patient Population 17.7. France Antidiabetics Market Analysis 17.7.1. Value Proportion Analysis by Market Taxonomy 17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.7.2.1. By Product 17.7.2.2. By Route of Administration 17.7.2.3. By Patient Population 17.8. Italy Antidiabetics Market Analysis 17.8.1. Value Proportion Analysis by Market Taxonomy 17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.8.2.1. By Product 17.8.2.2. By Route of Administration 17.8.2.3. By Patient Population 17.9. BENELUX Antidiabetics Market Analysis 17.9.1. Value Proportion Analysis by Market Taxonomy 17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.9.2.1. By Product 17.9.2.2. By Route of Administration 17.9.2.3. By Patient Population 17.10. UK Antidiabetics Market Analysis 17.10.1. Value Proportion Analysis by Market Taxonomy 17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.10.2.1. By Product 17.10.2.2. By Route of Administration 17.10.2.3. By Patient Population 17.11. Nordic Countries Antidiabetics Market Analysis 17.11.1. Value Proportion Analysis by Market Taxonomy 17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.11.2.1. By Product 17.11.2.2. By Route of Administration 17.11.2.3. By Patient Population 17.12. China Antidiabetics Market Analysis 17.12.1. Value Proportion Analysis by Market Taxonomy 17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.12.2.1. By Product 17.12.2.2. By Route of Administration 17.12.2.3. By Patient Population 17.13. Japan Antidiabetics Market Analysis 17.13.1. Value Proportion Analysis by Market Taxonomy 17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.13.2.1. By Product 17.13.2.2. By Route of Administration 17.13.2.3. By Patient Population 17.14. South Korea Antidiabetics Market Analysis 17.14.1. Value Proportion Analysis by Market Taxonomy 17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.14.2.1. By Product 17.14.2.2. By Route of Administration 17.14.2.3. By Patient Population 17.15. GCC Countries Antidiabetics Market Analysis 17.15.1. Value Proportion Analysis by Market Taxonomy 17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.15.2.1. By Product 17.15.2.2. By Route of Administration 17.15.2.3. By Patient Population 17.16. South Africa Antidiabetics Market Analysis 17.16.1. Value Proportion Analysis by Market Taxonomy 17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.16.2.1. By Product 17.16.2.2. By Route of Administration 17.16.2.3. By Patient Population 17.17. Turkey Antidiabetics Market Analysis 17.17.1. Value Proportion Analysis by Market Taxonomy 17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.17.2.1. By Product 17.17.2.2. By Route of Administration 17.17.2.3. By Patient Population 17.17.3. Competition Landscape and Player Concentration in the Country 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Concentration 18.3. Market Share Analysis of Top Players 18.4. Market Presence Analysis 18.4.1. By Regional footprint of Players 18.4.2. Product footprint by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. AstraZeneca 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Sales Footprint 19.3.1.4. Strategy Overview 19.3.2. Bayer Corporation 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Sales Footprint 19.3.2.4. Strategy Overview 19.3.3. Boehringer Ingelheim 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Sales Footprint 19.3.3.4. Strategy Overview 19.3.4. Bristol-Myers Squibb 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Sales Footprint 19.3.4.4. Strategy Overview 19.3.5. Eli Lilly 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Sales Footprint 19.3.5.4. Strategy Overview 19.3.6. Halozyme Therapeutics 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Sales Footprint 19.3.6.4. Strategy Overview 19.3.7. Johnson & Johnson 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Sales Footprint 19.3.7.4. Strategy Overview 19.3.8. Merck & Co. Inc. 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Sales Footprint 19.3.8.4. Strategy Overview 19.3.9. Novartis AG 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Sales Footprint 19.3.9.4. Strategy Overview 19.3.10. Novo Nordisk 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Sales Footprint 19.3.10.4. Strategy Overview 19.3.11. Oramed Pharmaceuticals Inc. 19.3.11.1. Overview 19.3.11.2. Product Portfolio 19.3.11.3. Sales Footprint 19.3.11.4. Strategy Overview 19.3.12. Pfizer 19.3.12.1. Overview 19.3.12.2. Product Portfolio 19.3.12.3. Sales Footprint 19.3.12.4. Strategy Overview 19.3.13. Sanofi 19.3.13.1. Overview 19.3.13.2. Product Portfolio 19.3.13.3. Sales Footprint 19.3.13.4. Strategy Overview 19.3.14. Takeda Pharmaceutical 19.3.14.1. Overview 19.3.14.2. Product Portfolio 19.3.14.3. Sales Footprint 19.3.14.4. Strategy Overview 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Antidiabetics Market
